Logo
x

Search

Subscribe Now

Fresenius Kabi

Fresenius Kabi Reports the Reguatory Submission to the US FDA for the Aurora Xi Plasmapheresis System Software Version 2.0 with New Nomogram

Fresenius Kabi Reports the Reguatory Submission to the US FDA for the Aurora Xi Plasmapheresis System Software Version 2.0 with Ne...

  • November 22, 2024
Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)

Fresenius Kabi and Formycon Report the US FDA’s Approval of Otulfi (Biosimilar, Stelara)

  • October 1, 2024
Fresenius Reports the US FDA’s BLA Acceptance of FKS518 (Biosimilar, Denosumab)

Fresenius Reports the US FDA’s BLA Acceptance of FKS518 (Biosimilar, Denosumab)

  • May 28, 2024
Fresenius Kabi Launches Tyenne (Biosimilar, Actemra; IV) to Treat Chronic Autoimmune diseases

Fresenius Kabi Launches Tyenne (Biosimilar, Actemra; IV) to Treat Chronic Autoimmune diseases

  • April 15, 2024
Fresenius Kabi Reports the US FDA’s Approval for Tyenne (Biosimilar, tocilizumab-aazg) as a Treatment of Immunological and Oncological Indications

Fresenius Kabi Reports the US FDA’s Approval for Tyenne (Biosimilar, tocilizumab-aazg) as a Treatment of Immunological and Oncolog...

  • March 7, 2024
Fresenius Kabi Launches Tyenne, Europe’s First Tocilizumab Biosimilar for Inflammatory Diseases and COVID-19

Fresenius Kabi Launches Tyenne, Europe’s First Tocilizumab Biosimilar for Inflammatory Diseases and COVID-19

  • November 1, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.